ARM Regen Med Investor Day: Clinical Outlook in Cardiovascular Disease Panel
â˘
0 gefällt mirâ˘290 views
Presisdent Marc Hedrick presents as part of the Cardiac Cell Therapy at the 1st Annual Regen Med Investor Day
Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Andere mochten auch
Andere mochten auch (9)
Ăhnlich wie ARM Regen Med Investor Day: Clinical Outlook in Cardiovascular Disease Panel
Ăhnlich wie ARM Regen Med Investor Day: Clinical Outlook in Cardiovascular Disease Panel (20)
KĂźrzlich hochgeladen
KĂźrzlich hochgeladen (20)
ARM Regen Med Investor Day: Clinical Outlook in Cardiovascular Disease Panel
- 1. 1st Annual Regen Med Investor Day Clinical Outlooks in Cardiovascular Disease Marc Hedrick, MD Cytori Therapeutics (NASDAQ:CYTX) President April 17, 2013
- 2. Safe Harbor Statement This presentation contains certain âforward-looking statementsâ about Cytori Therapeutics, Inc. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation involve known and unknown risks that relate to Cytoriâs future events or future financial performance and the actual results could differ materially from those discussed in this presentation. Risks and uncertainties that may cause Cytori's actual results to differ materially from those discussed in the presentation can be found in the "Risk Factors" section of Cytoriâs Form 10-K, Forms 10-Q and other filings with the United States Securities and Exchange Commission. We would advise reading our most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the United States Securities and Exchange Commission for a more detailed description of these risks. The forward-looking statements contained in this presentation represent Cytoriâs estimates and assumptions only as of the date of this presentation and Cytori undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in Cytoriâs expectations.
- 3. Cytori Cell Therapy: Unique Attributes Proprietary formulation of ADRCs â˘Autologous â˘Mixed cell population â˘Various mechanisms â˘Patented process â˘Virtually âoff the shelfâ
- 4. Cytori Cell Therapy: Heterogeneity Vascular Mechanisms of Action Smooth Tissue Muscle Cells Macrophages 9% 23% ⢠Paracrine (local GF Endothelial delivery) Cells 7% ⢠Differentiation ⢠Inflammatory modulation ⢠Angiogenesis ⢠Wound healing White Blood CD34+/ Cells CD31- Stem Cells 2% 22% 37%
- 5. Cytori Cell Therapy: Cardiovascular Trials EU Pilot US Pilot Pivotal Complete In Progress Acute MI APOLLO ADVANCE N = 14, Europe N = 216, Europe Complete In Progress Preliminary Chronic Myocardial ATHENA II PRECISE ATHENA Ischemia N=TBD, N = 27, Europe N = 45, USA International Summary from European Pilot Trials ⢠AMI- safe and trend toward reduction in infarct size, favorable remodeling ⢠HF & CMI- safe & statistically significant stabilization in Max VO2
- 6. Cytori Cell Therapy: Economics Procedures / Est. Consumable Est. Consumable Est. Revenue Year ASP Gross Profit 100,000 $10,000 $1 Billion $800 + Million System: ⢠Low six figure ASP (current generation) ⢠Next-generation system COGS~ $10,000, flexible model Per-procedure consumable: ⢠$8,000-$12,000 for vascular indications ⢠>80% GM